These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28508149)

  • 1. Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.
    Gonzalez-Cano L; Menzl I; Tisserand J; Nicklas S; Schwamborn JC
    Mol Neurobiol; 2018 Apr; 55(4):3490-3498. PubMed ID: 28508149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.
    Gehrke S; Imai Y; Sokol N; Lu B
    Nature; 2010 Jul; 466(7306):637-41. PubMed ID: 20671708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2.
    Rudenko IN; Kaganovich A; Langston RG; Beilina A; Ndukwe K; Kumaran R; Dillman AA; Chia R; Cookson MR
    Biochem J; 2017 Apr; 474(9):1547-1558. PubMed ID: 28320779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.
    Braunger LJ; Knab F; Gasser T
    J Parkinsons Dis; 2024; 14(5):977-991. PubMed ID: 38848197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
    Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
    Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32.
    Pavlou MAS; Colombo N; Fuertes-Alvarez S; Nicklas S; Cano LG; Marín MC; Goncalves J; Schwamborn JC
    Mol Neurobiol; 2017 Aug; 54(6):4257-4270. PubMed ID: 27339877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
    Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
    Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 Phosphorylation: Behind the Scenes.
    De Wit T; Baekelandt V; Lobbestael E
    Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.